SOLICITATION NOTICE
A -- ACCESS TO NATIONAL CARDIOVASCULAR DATA REGISTRY
- Notice Date
- 5/8/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Division of Contracts and Procurement Management, Office of Facilities, Acquisitions, and Central Svcs 5600 Fishers Lane, HFA-511, Rockville, MD, 20857
- ZIP Code
- 20857
- Solicitation Number
- Reference-Number-272904
- Response Due
- 5/22/2002
- Archive Date
- 6/6/2002
- Point of Contact
- Ida Cofield, Contract Specialist, Phone (301) 827-7156, Fax (301) 827-7151,
- E-Mail Address
-
icofield@oc.fda.gov
- Small Business Set-Aside
- Total Small Business
- Description
- This is a combined synopsis /solicitation for commercial items or services prepared in accordance with the format in FAR Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a written solicitation will not be issued. This solicitation is issued as a Request for Quote (RFQ) No. 272904. The solicitation clauses and provisions are those in effect through Federal Acquisition Circular 97-27. The Standard Industrial Classification (SIC) Code for this acquisition is 7389 and the North American Classification System (NAICS) Code is 541990. The Food and Drug Administration (FDA) is issuing a Request for Quote on a sole source basis to the American College of Cardiology (ACC) for the following service: Access to National Cardiovascular Data Registry. Specific data to be included in this are (1) Demographic data: Age, race, and gender, (2) Adverse outcomes: Bleeding, pseudoaneurvsm, AV fistula, loss of distal pulse, death (follow-up visit included), (3) Potential co variables: NYHA classification, cardiac cath or PCI status, body surface area, History of diabetes, hypertension or peripheral vascular disease, (4) Procedure type, and (5) Cath data: Type of hemostasis device. In addition the ACC will add some date items to their current registry, so that these too can be analyzed. The added items will include (1) Hemostasis device by manufacturer, (2) Adverse outcomes: Information that will allow distinction between serious blood loss and haematoma without serious blood loss; infection; occlusion; dissection, (3) history of current estrogen use, (4) Coagulation status (ACT at end of procedure) and, (5) History of previous PCI within past 90 days. The period of performance will be from date of award through one year. The following FAR Clauses shall apply to this solicitation 52.212-1 Instructions to Offerors-Commercial, 52.213-4 Contract Terms and Conditions-Commercial Items, and 52.232-33 Electronic Funds Transfers. All responsible sources that can provide and meet the above requirements shall submit written quotations by the due date referenced above. The award is being issued on a sole source basis because the service is only available from the contractor with no resellers. FAR provisions can be found at the following website:http://www/arnet.gov.
- Place of Performance
- Address: FOOD AND DRUG ADMINISTRATION, CENTER FOR DIVICES AND RADIOLOGCAL HEALTH, OFFICE OF SURVEILLANCE AND BIOMETRICS, 1350 PICCARD DRIVE, ROOM 330Y, ROCKVILLE, MARYLAND
- Zip Code: 20857
- Country: US
- Zip Code: 20857
- Record
- SN00073438-W 20020510/020508213112 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |